Business Wire

Takeda Reports Results for Three Quarters (April-December) of FY2015,Reaffirms Management Guidance for the Full Year

Del

Takeda Pharmaceutical Company Limited (TOKYO:4502):

Results of April to December period reaffirms full-year management guidance

  • Underlying revenue +3.8% year-to-year (reported revenue growing +4.0% to 1,393.3 billion yen), led by strong performance in the U.S. and the emerging markets
  • Underlying Core Earnings +1.5% year-to-year (operating profit -15.9% to 167.5 billion yen)
  • Underlying Core EPS +17.3% year-to year (reported EPS growing +43% to 145 yen)

Contribution of Takeda's growth drivers

  • Consolidated underlying revenue of gastroenterology, oncology and emerging markets – Takeda's growth drivers – is +8.5% year-to-year
  • Gastroenterology underlying revenue +24.7%, oncology up +0.4% year-to-year
  • Emerging markets underlying revenue +5.7% year-to-year, with particularly strong contributions from Russia and China

Growth of innovative new products to offset loss of exclusivity impact

  • ENTYVIO® is on the way to over $2 bln in peak sales, BRINTELLIX® and ADCETRIS® show steady growth
  • AZILVA® and LOTRIGA® are contributing to Japan business.

Efficiency gains continue

  • Project Summit achieved 21 billion yen of cost savings in the April-December 2015 period, exceeding the full-year target

For FY2015 full year reported forecast, operating profit upgraded, others unchanged

  • Based on performance through three quarters, Takeda raised the full year reported forecast for operating profit to 120 billion yen

Affirming management guidance in FY2015

  • Low single-digit underlying revenue growth in FY2015, with underlying core earnings growth higher than underlying revenue growth, and underlying core EPS growth higher than underlying core earnings growth

Christophe Weber, President and Chief Executive Officer of Takeda, commented:
"Through three quarters (April to December) of FY2015, Takeda's turnaround continues, with underlying revenue growth of +3.8% year-to-year, led by our growth drivers of gastroenterology, oncology and emerging markets. With the global launch of new products such as ENTYVIO and NINLARO, Takeda is on the right track to deliver revenue growth and improved profitability. On the basis of our three quarters results, we confirm our full-year management guidance."

Key figures for three quarters

 

of FY2015

  FY 2014   FY 2015   Growth
billion yen Apr-Dec Apr-Dec     Underlying2
Revenue 1,340.0 1,393.3 +4.0% +3.8%
Operating Profit 199.1 167.5 -15.9%
Core Earnings 1 276.5 269.8 -2.4% +1.5%
Net Profit 3 79.7 113.6 +42.5%
EPS 101 yen 145 yen +43.0%
Core EPS   216 yen   241 yen   +11.4%   +17.3%

1

  Core Earnings is calculated from operating profit by excluding the impact of exceptional items, such as purchase accounting, amortization and impairment loss of intangible assets, restructuring costs and major litigation costs.

2

Underlying performance aims at understanding the real performance of the business. Underlying Revenue and Underlying Core Earnings excludes the same as above and adjusted for acquisitions/divestments and foreign exchange.

3

Attributable to the owners of the company
 

Underlying revenue growth in the 3Q (April to December, 2015) was +3.8% year-to-year, Underlying Core Earnings was +1.5% and Underlying Core EPS was +17.3%, with no change in Takeda's management guidance for FY2015. Reported revenue grew +4.0% year-to-year to 1,393.3 billion yen. An increase in expenses to new global products as well as a decrease in other income such as reversal of COLCRYS® contingent consideration and gain from sales of real estate in 2014, resulted in a year-to-year decline in Operating Profit by 31.6 billion yen. Despite the decrease in operating profit, consolidated net profit was 113.6 billion yen, an increase of 33.9 billion yen (+42.5% year-to-year), mainly due to the decrease in income tax expenses.

Underlying revenue growth was mainly driven by Takeda's growth drivers; gastroenterology, oncology and emerging markets. The three account for almost 50% of Takeda's revenue. Gastroenterology grew by +24.7% year-to-year, driven by ENTYVIO®. Oncology revenue, including VELCADE® and ADCETRIS®, increased by +0.4%. Launched in the U.S. in December, NINLARO®, a highly innovative once-weekly capsule for multiple myeloma, is expected to provide a significant contribution to Takeda's mid- to long-term sustained growth. Emerging Markets revenue grew by +5.7% year-to-year, led by Value Brands (branded generics and Over-The-Counter medicines), with strong growth in Russia and China. Performance in the U.S. (+11.6% year-to-year underlying revenue growth) also contributed to revenue growth. In Japan, under the increasing generic pressure, underlying revenue declined -1.7% year-to-year, but the year-to-year revenue declines moderated, led by the contribution of AZILVA® and LOTRIGA®.

Project Summit – a company-wide strategic initiative to increase efficiency – continued to produce results, with 21 billion yen savings in the three quarters period, exceeding the full year target.

ENTYVIO® and NINLARO® are expected to be key global contributors to Takeda's sales growth. In Japan, a new business venture with Teva Pharmaceutical Industries Ltd. will be established in or after April 2016 to deliver Teva's high-quality generic medicines and Takeda's long-listed products to patients. It is expected to meet wide-ranged needs of patients and correspond to the growing importance of generics in Japan, while Takeda will further focus on innovative new medicines, such as AZILVA®, LOTRIGA®, TAKECAB®, NESINA® and ZAFATEK®.

As part of its ongoing effort to improve the R&D productivity, Takeda announced that its top priority is to be a leader in three therapeutic areas, Oncology, Gastroenterology and Central Nervous System. In addition, it will deliver maximum, targeted value in Specialty CV and an innovative business and global health approach in Vaccines.

Takeda affirmed its management guidance for FY2015, leading to long-term sales and profit growth, and raised the full-year reported forecast of operating profit to 120 billion yen, based on the three quarters' results.

Management Guidance for FY2015

   
  Underlying Growth
Underlying Revenue Low single digit
Underlying Core Earnings Higher than underlying revenue growth
Underlying Core EPS   Higher than underlying core earnings growth
 

FY2015 full year reported

 

forecast: operating profit revised, others unchanged

billion yen Previous

Forecast

  Change   Revised

Forecast

Revenue 1,820.0 1,820.0
R&D expenses 330.0 330.0
Operating profit 105.0 +15.0(+14.3%) 120.0
Profit before tax 115.0 115.0
Net profit for the year 68.0 68.0
EPS   87 yen     87 yen
 

For more details on Takeda’s FY2015 3Q results and other financial information, please visit http://www.takeda.com/investor-information/results/

About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda (TOKYO:4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Information about Takeda is available on www.takeda.com.

Contact information

Takeda Pharmaceutical Company Limited
Investor Relations
Noriko Higuchi, +81-(0)3-3278-2306
noriko.higuchi@takeda.com
or
Media Relations
Japanese media
Tsuyoshi Tada, +81 (0)3-3278-2417,
tsuyoshi.tada@takeda.com
or
Media outside Japan
Jocelyn Gerst, +1-224-554-5542
jocelyn.gerst@takeda.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Sparkol Launches VideoScribe 318.10.2017 13:24Pressemelding

Introducing VideoScribe Version 3 by Sparkol. Already used by over two million people across the world to create engaging explainer videos, Version 3 of the highly intuitive software comes packed full of new features, including: An improved user experience and slick UI - animate easier than ever before Enhanced search - find exactly the image you need in record time Intelligent image recommendations - focus your creativity on your video instead Smoother performance - maximum productivity when using the software VideoScribe customers include the world’s largest brands (HP, BBC, Sky and the University of British Columbia), businesses across every sector, leading education providers, award-winning teachers, charities, campaigners, and coun

Piraeus Bank: Agreement for the Sale of Serbian Operations18.10.2017 13:06Pressemelding

Piraeus Bank announces that it has entered into an agreement to sell its Serbian banking and leasing operations to Direktna Banka A.D., a local Serbian banking group that has been strongly growing its presence in the market, for a total cash consideration between €58mn up to €61mn, depending on the financial performance of the divested assets until completion of the transaction, through a combination of direct sale price and simultaneous reduction of capital in Piraeus Bank Beograd AD. The transaction is conditional upon the usual corporate and regulatory approvals, including those of the National Bank of Serbia and the Hellenic Financial Stability Fund. The transaction represents another step towards the implementation of Piraeus Bank’s Restructuring Plan commitments, as those were agreed with the Directorate General of Competition of the European Commission. The transactio

Introducing InVision Studio, The World’s Most Powerful Screen Design Tool18.10.2017 13:01Pressemelding

InVision, the product design platform powering the world’s best digital experiences, today introduced Studio, a powerful new tool that will change the way screen design is done. InVision Studio was created by working closely with the world’s best design teams and finding inspiration in how they create beloved digital products. The launch of Studio comes at a time when modern organizations are shaping and redefining entire markets through their focus on digital customer experience. InVision already powers the product design process of more than 3 million people at tens of thousands of companies, including eighty percent of the Fortune 100 and brands like Airbnb, Uber, HBO, Amazon, IBM, Nike, and Slack. This new product reflects a major evolution of the digital product design workflow. With Studio, InVision has developed an end-to-end platform for designing digit

SmartStream and Credit Suisse Expand their Agreement from the Processing of Invoices and Reconciliations to Now Include Listed Derivatives Brokerage Fees18.10.2017 12:00Pressemelding

SmartStream Technologies, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announced that its original agreement with Credit Suisse was recently expanded to include the processing of Listed Derivatives Brokerage fees which began in February of this year. This expansion in SmartStream’s partnership with Credit Suisse complements its existing managed service solution for the processing of invoices and reconciliations within Credit Suisse’s OTC Fixed Income Derivatives, US Listed Equity Options and Cash Equities businesses across brokerage, clearing and exchange fees operations, which began in June of 2016. The managed service enables the bank to advance the operational efficiencies created through the use of the utility-based solutions offered by SmartStream, utilizing their proprietary execution fees and expense management software. By centralizing the ent

Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach18.10.2017 11:30Pressemelding

Biogen (NASDAQ: BIIB) confirms its comprehensive approach to tackle multiple sclerosis (MS) at the seventh Joint Meeting of the European Committee for Treatment and Research in MS and Americas Committee for Treatment and Research in MS (ECTRIMS-ACTRIMS; 25 – 28 October). “With more than 25 years of scientific leadership in MS, Biogen’s commitment is unwavering,” said Michael Ehlers, executive vice president, Research & Development at Biogen. “Our expertise puts Biogen in a unique position with a comprehensive approach including active research and clinical development on how to repair the damage to the central nervous system from relapsing forms of MS, a portfolio of new drug candidates that we are advancing to the clinic, our collaboration to identify a digital biomarker, our focus to advance understanding of the disease through global data collection with MS PATHS, active pursuit

Scientist.com Collaborates With UKCRC Tissue Directory and Coordination Centre to Ensure Quality of Human Biosample Acquisition Globally18.10.2017 11:01Pressemelding

Scientist.com, the world’s leading marketplace for outsourced scientific services, today announced that it is entering into a collaboration with the UKCRC Tissue Directory and Coordination Centre (UKCRC TDCC) to support the work of biobanks throughout the United Kingdom. The partnership will enable drug R&D to move forward more quickly by making large collections of prescreened human biological samples available for scientific research. Through the new COMPLI™ feature, Scientist.com provides a simple, efficient and effective way of increasing the visibility and accessibility of biobanks’ human biological samples collections, which support new medical research. COMPLI™ introduces a common, comprehensive process and supply agreement supporting access to human biosamples. The goal is to enable biobanks to more easily connect with researchers in the pharmaceutical and biotech indust

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom